It’s Very Difficult to Get Access to Antiviral COVID Treatments

January 26, 2022

(Axios) – Antiviral COVID treatments are hailed as a pandemic game-changer, but they’re currently in very short supply — and that’s only one of several barriers to access for high-risk patients. The big picture: Even when supply ramps up, it will still be tricky to connect some of the most vulnerable patients to the pills without changes to the process. Why it matters: Recently approved antivirals reduce the risk of hospitalization and death by up to 89%. (Read More)